deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT05458609

Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep

Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep: A Randomized, Double-Blind, Placebo- Controlled Study

Sponsor: Baylor College of Medicine

Conditions Alcohol Use Disorder
Interventions Lemborexant 10 mg Naltrexone
Updated 5 times since 2022 Last updated: Feb 26, 2024 Started: Feb 9, 2023 Primary completion: Jan 30, 2024 Completion: Jan 30, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Alcohol Use Disorder, this trial is completed. The trial is conducted by Baylor College of Medicine and has accumulated 5 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Sep 2022 – ~Mar 2023 · 6 months · monthly snapshotNot Yet Recruiting~Mar 2023 – ~Mar 2024 · 12 months · monthly snapshotEnrolling By Invitation~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Mar 2024 — Jul 2024 [monthly]

    Completed PHASE3

    Status: Enrolling By Invitation → Completed

  4. Mar 2023 — Mar 2024 [monthly]

    Enrolling By Invitation PHASE3

    Status: Not Yet Recruiting → Enrolling By Invitation

  5. Sep 2022 — Mar 2023 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Baylor College of Medicine
Data source: Baylor College of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations